A newly published study found that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible for treating loss of vision resulting from central retinal vein occlusion (CRVO) ...
Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing ...
Prolonged near work in low luminance may accelerate myopia primarily by limiting retinal illumination through sustained accommodative miosis rather than by electronic screens per se.
At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
Ophthalmology Times, hosted by Douglas D. Koch, MD, Professor and Allen, Mosbacher, and Law Chair in Ophthalmology at the ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. EYE PCR’s fixOflex is now eligible for European ...
Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...
A discussion of his situation led to the selection of the enVista Envy IOL. One month postoperatively, the patient achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results